COVID-19 与先天性免疫缺陷
COVID-19 and Inborn Errors of Immunity.
机构信息
Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
出版信息
Physiology (Bethesda). 2022 Nov 1;37(6):0. doi: 10.1152/physiol.00016.2022. Epub 2022 Aug 9.
Abstract
Inborn errors of immunity (IEI) are a heterogeneous group of disorders affecting immune host defense and immunoregulation. Considering the predisposition to develop severe and chronic infections, it is crucial to understand the clinical evolution of COVID-19 in IEI patients. This review analyzes clinical outcomes following SARS-CoV-2 infection, as well as response to COVID-19 vaccines in patients with IEI.
摘要
先天性免疫缺陷（IEI）是一组影响宿主免疫防御和免疫调节的异质性疾病。鉴于易发生严重和慢性感染，了解 IEI 患者 COVID-19 的临床演变至关重要。本综述分析了 SARS-CoV-2 感染后的临床结局，以及 IEI 患者对 COVID-19 疫苗的反应。
相似文献
1
COVID-19 and Inborn Errors of Immunity.COVID-19 与先天性免疫缺陷
Physiology (Bethesda). 2022 Nov 1;37(6):0. doi: 10.1152/physiol.00016.2022. Epub 2022 Aug 9.
2
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity.辉瑞-BioNTech COVID-19 疫苗在先天性免疫缺陷患者中的免疫原性。
J Allergy Clin Immunol. 2021 Sep;148(3):739-749. doi: 10.1016/j.jaci.2021.05.029. Epub 2021 Jun 1.
3
Acute and long-term immune responses to SARS-CoV-2 infection in unvaccinated children and young adults with inborn errors of immunity.未接种疫苗的先天性免疫缺陷儿童和年轻人中对 SARS-CoV-2 感染的急性和长期免疫反应。
Front Immunol. 2023 Jan 20;14:1084630. doi: 10.3389/fimmu.2023.1084630. eCollection 2023.
4
COVID-19 in the Context of Inborn Errors of Immunity: a Case Series of 31 Patients from Mexico.COVID-19 与先天性免疫缺陷：来自墨西哥的 31 例患者的病例系列。
J Clin Immunol. 2021 Oct;41(7):1463-1478. doi: 10.1007/s10875-021-01077-5. Epub 2021 Jun 10.
5
Coronavirus disease 2019 in patients with inborn errors of immunity: An international study.先天性免疫缺陷患者的 2019 年冠状病毒病：一项国际研究。
J Allergy Clin Immunol. 2021 Feb;147(2):520-531. doi: 10.1016/j.jaci.2020.09.010. Epub 2020 Sep 24.
6
SARS-CoV-2 infection in patients with inborn errors of immunity due to DNA repair defects.SARS-CoV-2 感染与 DNA 修复缺陷导致的固有免疫缺陷患者。
Acta Biochim Biophys Sin (Shanghai). 2022 Jun 25;54(6):836-846. doi: 10.3724/abbs.2022071.
7
Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity.严重急性呼吸综合征冠状病毒 2 感染和 COVID-19 对先天性免疫缺陷病患者的影响。
J Allergy Clin Immunol. 2023 Apr;151(4):818-831. doi: 10.1016/j.jaci.2022.11.010. Epub 2022 Dec 13.
8
Outcome of SARS-CoV-2 Infection in 121 Patients with Inborn Errors of Immunity: A Cross-Sectional Study.先天性免疫缺陷患者 121 例 SARS-CoV-2 感染的结局：一项横断面研究。
J Clin Immunol. 2021 Oct;41(7):1479-1489. doi: 10.1007/s10875-021-01066-8. Epub 2021 Jun 23.
9
The spectrum of side effects associated with COVID-19 vaccines in patients with inborn errors of immunity.与先天性免疫缺陷患者 COVID-19 疫苗相关的副作用谱。
Clin Immunol. 2024 Feb;259:109878. doi: 10.1016/j.clim.2023.109878. Epub 2023 Dec 18.
10
Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19.免疫先天缺陷和重症/危重症 COVID-19 患儿的遗传学和免疫学评估。
J Allergy Clin Immunol. 2022 Nov;150(5):1059-1073. doi: 10.1016/j.jaci.2022.09.005. Epub 2022 Sep 13.
引用本文的文献
1
T and B cell responses in different immunization scenarios for COVID-19: a narrative review.COVID-19不同免疫方案中的T细胞和B细胞反应：一项叙述性综述
Front Immunol. 2025 Mar 18;16:1535014. doi: 10.3389/fimmu.2025.1535014. eCollection 2025.
2
Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls.与健康对照相比，免疫缺陷患者接种5剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗后T细胞免疫增强，体液反应降低。
Front Immunol. 2025 Mar 6;16:1538453. doi: 10.3389/fimmu.2025.1538453. eCollection 2025.
3
Clinical feature of omicron infection in children with inborn errors of immunity in China.中国先天性免疫缺陷患儿感染奥密克戎的临床特征。
Front Immunol. 2024 Jul 23;15:1420547. doi: 10.3389/fimmu.2024.1420547. eCollection 2024.
4
COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report.COVID-19 疫苗接种可降低原发性免疫缺陷病患者的 COVID-19 住院和重症监护需求：一项 USIDNET 报告。
J Clin Immunol. 2024 Apr 5;44(4):86. doi: 10.1007/s10875-023-01613-5.
5
Stuck in pandemic uncertainty: a review of the persistent effects of COVID-19 infection in immune-deficient people.困于疫情不确定性之中：免疫缺陷人群中 COVID-19 感染的持续影响综述。
Clin Microbiol Infect. 2024 Aug;30(8):1007-1011. doi: 10.1016/j.cmi.2024.03.027. Epub 2024 Mar 27.
6
Human genetic determinants of COVID-19 in Brazil: challenges and future plans.巴西新冠病毒病的人类遗传决定因素：挑战与未来计划
Genet Mol Biol. 2024 Jan 15;46(3 Suppl 1):e20230128. doi: 10.1590/1678-4685-GMB-2023-0128. eCollection 2024.
7
Perturbations of the T-cell receptor repertoire in response to SARS-CoV-2 in immunocompetent and immunocompromised individuals.免疫功能正常和免疫功能低下个体对 SARS-CoV-2 的 T 细胞受体库的改变。
J Allergy Clin Immunol. 2024 Jun;153(6):1655-1667. doi: 10.1016/j.jaci.2023.12.011. Epub 2023 Dec 27.
8
SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience.替沙格韦单抗/西加韦单抗（AZD7442）用于 SARS-CoV-2 暴露前预防可提供抗体缺陷型先天性免疫缺陷病的保护：真实世界经验。
Front Immunol. 2023 Oct 26;14:1249462. doi: 10.3389/fimmu.2023.1249462. eCollection 2023.
9
SARS-CoV-2 Infection and Response to COVID-19 Vaccination in Patients With Primary Immunodeficiencies.原发性免疫缺陷病患者的 SARS-CoV-2 感染和对 COVID-19 疫苗接种的反应。
J Infect Dis. 2023 Aug 4;228(Suppl 1):S24-S33. doi: 10.1093/infdis/jiad145.
10
The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic.在持续的大流行中测量新冠病毒特异性T细胞反应的重要性。
Pathogens. 2023 Jun 22;12(7):862. doi: 10.3390/pathogens12070862.
本文引用的文献
1
Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia.中和I型干扰素的自身抗体可能与托珠单抗治疗COVID-19肺炎的疗效相关。
J Clin Immunol. 2022 Aug;42(6):1107-1110. doi: 10.1007/s10875-022-01295-5. Epub 2022 Jun 8.
2
Comparisons of Clinical Features and Outcomes of COVID-19 between Patients with Pediatric Onset Inflammatory Rheumatic Diseases and Healthy Children.儿童期起病的炎性风湿性疾病患者与健康儿童新型冠状病毒肺炎临床特征及结局的比较
J Clin Med. 2022 Apr 9;11(8):2102. doi: 10.3390/jcm11082102.
3
The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet).严重急性呼吸综合征冠状病毒 2 感染对先天性免疫缺陷患者的影响：意大利原发性免疫缺陷网络（IPINet）的经验。
J Clin Immunol. 2022 Jul;42(5):935-946. doi: 10.1007/s10875-022-01264-y. Epub 2022 Apr 20.
4
Observations and Perspectives on Adaptive Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的适应性免疫的观察和观点。
Clin Infect Dis. 2022 Aug 15;75(Suppl 1):S24-S29. doi: 10.1093/cid/ciac310.
5
SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.严重和致命的新型冠状病毒肺炎（COVID-19）中，原发性抗体缺陷患者无特异性体液免疫时的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）T细胞反应
Front Immunol. 2022 Mar 10;13:840126. doi: 10.3389/fimmu.2022.840126. eCollection 2022.
6
Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity - Results From a Multicenter Nationwide Study.先天性免疫缺陷患者发生重症 COVID-19 和住院的危险因素：一项多中心全国性研究结果
Front Immunol. 2022 Feb 28;13:835770. doi: 10.3389/fimmu.2022.835770. eCollection 2022.
7
The Effect of COVID-19 Pandemic on Patients with Primary Immunodeficiency: A Cohort Study.COVID-19 大流行对原发性免疫缺陷患者的影响：一项队列研究。
Iran J Med Sci. 2022 Mar;47(2):162-166. doi: 10.30476/IJMS.2022.92862.2415.
8
Immunogenicity of a third COVID-19 messenger RNA vaccine dose in primary immunodeficiency disorder patients with functional B-cell defects.第三剂新冠信使核糖核酸疫苗在具有功能性B细胞缺陷的原发性免疫缺陷病患者中的免疫原性
J Allergy Clin Immunol Pract. 2022 May;10(5):1385-1388.e2. doi: 10.1016/j.jaip.2022.02.030. Epub 2022 Mar 5.
9
Antigen-Specific CD4 T-Cell Activation in Primary Antibody Deficiency After BNT162b2 mRNA COVID-19 Vaccination.BNT162b2 mRNA COVID-19 疫苗接种后原发性抗体缺陷患者的抗原特异性 CD4 T 细胞激活。
Front Immunol. 2022 Feb 14;13:827048. doi: 10.3389/fimmu.2022.827048. eCollection 2022.
10
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations.COVID-19 与风湿性疾病：风险、结局、治疗考量。
Nat Rev Rheumatol. 2022 Apr;18(4):191-204. doi: 10.1038/s41584-022-00755-x. Epub 2022 Feb 25.
Zotero 插件